The multi-day event united global creators in Hollywood for a content creation competition experience to educate and entertain consumers on healthy skin habits.NEW YORK,...
The iconic Seoul-based brand introduces a first-of-its-kind flagship where cutting-edge architecture meets AI-based, made-for-you beautySEOUL, South Korea, June 5, 2026 /PRNewswire/ -- After 18 months...
Achievement highlights more than 17 years of growth in personalized, accessible, and results-driven skin careSCOTTSDALE, Ariz., June 4, 2026 /PRNewswire/ -- Massage Envy, a national...
BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced data, comprising two posters and three abstracts, at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, demonstrating the clinical profile of dapirolizumab pegol (DZP), an investigational biologic in patients with systemic lupus erythematosus (SLE).
Specialty and Generic Medicines Leader Honored for Dedication to the Dermatology FieldNEW YORK, June 3, 2026 /PRNewswire/ -- On Tuesday evening at The Plaza...
IRVINE, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- iHerb, a globally renowned health and wellness e-commerce platform, which has been established for 29 years, recently launched its 618 Peak Shopping Festival (June 11-20) and offered a month-long discount program to give back to users in Hong Kong and Southeast Asia. The platform insists on direct sourcing from brands and self-operated warehouse delivery to ensure that products are genuine. It currently covers 185 countries and regions, with over 11 million active users, and its products include nearly 3,000 brands and over 50,000 premium items in areas such as dietary nutrition, sports and health, and beauty and personal care.
Warsaw, Poland – June 03, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotech that engineers precision antibodies to correct derailed immune pathways that drive autoimmune diseases and cancer, today announces positive interim data from its ongoing Phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class anti-CD89 antagonist, in patients diagnosed with Linear IgA Disease (LAD), a rare autoantibody-mediated skin disease.
Between 2018 and 2023, Dr Ivan Puah treated over 550 cases, addressing unique challenges in Singapore's multi-ethnic population. His study included diverse case profiles....
TAIPEI, June 2, 2026 /PRNewswire/ -- GIGABYTE, the world's leading computer brand, unveiled its next-generation gaming peripheral lineup at COMPUTEX 2026, led by the...